Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;83(2):579-586.
doi: 10.1016/j.jaad.2020.05.074. Epub 2020 May 19.

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment

Muskaan Sachdeva  1 , Asfandyar Mufti  2 , Khalad Maliyar  1 , Yuliya Lytvyn  1 , Jensen Yeung  3
Affiliations
Free PMC article

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment

Muskaan Sachdeva et al. J Am Acad Dermatol. 2020 Aug.
Free PMC article

Abstract

Background: While evidence suggests that hydroxychloroquine (HCQ) may decrease the viral load in patients with a COVID-19 infection, a number of case reports indicate adverse dermatologic effects of this potential treatment.

Objective: To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment.

Methods: Embase and MEDLINE were comprehensively searched for original studies examining adverse effects of HCQ treatment related to psoriasis. Participant demographics and details of HCQ administration and psoriasis diagnosis were extracted from 15 articles representing 18 patients.

Results: Women accounted for a significantly larger number of cases of psoriasis compared with men and unreported sex (14 [77.8%] vs 2 [11.1%] vs 2 [11.1%], respectively). In addition, 50% (n = 9) of the patients did not have a history of psoriasis before taking HCQ. Of the 18 patients, 9 (50.0%) experienced de novo psoriasis, 5 (27.8%) experienced exacerbation of psoriatic symptoms, and 4 (22.2%) had a relapse of psoriasis after HCQ administration.

Conclusion: HCQ treatment may result in induction, exacerbation, or relapse of psoriasis. Monitoring for adverse effects of HCQ treatment is necessary, and clinical trials are essential in characterizing the safety profile of HCQ use in patients with a COVID-19 infection.

Keywords: COVID-19; Plaquenil; exacerbation; hydroxychloroquine; induction; psoriasis; relapse.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Selection process for study inclusion in the systematic review.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Balak D., Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl) 2017;7:87–94. - PMC - PubMed
    1. Rainsford K.D., Parke A.L., Clifford-Rashotte M., Kean W.F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–269. - PubMed
    1. Ponticelli C., Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE) Expert Opin Drug Saf. 2017;16(3):411–419. - PubMed
    1. Costedoat-Chalumeau N., Dunogué B., Morel N., Le Guern V., Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 2014;43(6 Pt 2):e167–e180. - PubMed
    1. Olsen N.J., Schleich M.A., Karp D.R. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43(2):264–272. - PubMed

Publication types

MeSH terms